Appendix 1 (as supplied by the authors): Propensity Score Model Results of Probability of Using ARBs

Parameter	Estimate	Odds Ratios	95% CI Lower	95% CI Upper	P value
Age, per year	0.00293	1.003	1	1.006	0.03
Male	-0.2262	0.798	0.756	0.842	<.0001
Year of Index Date					
2000		1			
2001	-0.037	0.964	0.735	1.264	0.8
2002	0.3619	1.436	1.123	1.837	0.004
2003	0.6167	1.853	1.458	2.355	<.0001
2004	0.8102	2.248	1.777	2.845	<.0001
2005	0.8976	2.454	1.942	3.101	<.0001
2006	0.9743	2.649	2.095	3.35	<.0001
2007	1.1676	3.214	2.54	4.067	<.0001
2008	1.2802	3.598	2.844	4.55	<.0001
2009	1.4174	4.127	3.261	5.221	<.0001
2010	1.6193	5.05	3.99	6.391	<.0001
Month of Index Date					
January		1			
February	0.1092	1.115	0.979	1.271	0.1
March	0.0958	1.101	0.968	1.252	0.1
April	0.1846	1.203	1.055	1.371	0.006
May	0.1947	1.215	1.067	1.384	0.003
June	0.042	1.043	0.921	1.181	0.5
July	0.1852	1.203	1.062	1.363	0.004
August	0.0959	1.101	0.972	1.246	0.1
September	0.0912	1.096	0.966	1.242	0.2
October	0.1489	1.161	1.024	1.315	0.02
November	0.2025	1.225	1.08	1.388	0.002
December	0.2266	1.254	1.108	1.42	0.0004
Monthly income, NT dollars					
Dependent		1			
<19,100	-0.07	0.932	0.865	1.006	0.07
19,100–41,999	-0.0444	0.957	0.899	1.018	0.2
≥42,000	0.1687	1.184	1.058	1.324	0.003

Urbanization[a]					
Level 1		1			
Level 2	0.00372	1.004	0.952	1.059	0.9
Level 3	0.1661	1.181	1.037	1.344	0.01
Level 4 (rural area)	0.00328	1.003	0.745	1.351	1.0
Outpatient Visits, in the past one year					
0–5 visits		1			
6–10 visits	-0.1038	0.901	0.632	1.286	0.6
11–15 visits	-0.0245	0.976	0.69	1.38	0.9
>15 visits	-0.0904	0.914	0.649	1.285	0.6
Charlson Comorbidity Index Score[b]					
2		1			
3	0.0516	1.053	0.977	1.134	0.2
4	0.1251	1.133	1.042	1.232	0.003
≥ 5	0.2204	1.247	1.131	1.374	<.0001
Adapted Diabetes Complications Severity Index score[c]	0.00645	1.006	0.987	1.027	0.5
Duration of diabetes, months	-0.00038	1	0.999	1	0.3
Anti-diabetic drugs					
Acarbose inhibits enzymes	0.1439	1.155	1.054	1.265	0.002
Sulfonylurea	-0.0105	0.99	0.938	1.044	0.7
Insulin	-0.00478	0.995	0.887	1.117	0.9
Metformin	-0.1236	0.884	0.836	0.934	<.0001
Thiazolidinediones	0.4698	1.6	1.474	1.736	<.0001
Glinide	0.2951	1.343	1.201	1.502	<.0001
Dipeptidyl peptidase-4 inhibitor	0.8184	2.267	1.82	2.824	<.0001
Anti-hypertensive drug					
Alpha-blocker	0.1123	1.119	0.971	1.289	0.1
Beta-blocker	-0.0304	0.97	0.905	1.04	0.4
Calcium channel blocker	0.268	1.307	1.237	1.382	<.0001
Diuretics	-0.112	0.894	0.834	0.959	0.002
Other anti-hypertensive drug	-0.5127	0.599	0.485	0.739	<.0001
Other concomitant medications					
Aspirin	0.025	1.025	0.957	1.098	0.5
Clopidogrel	0.4613	1.586	1.144	2.199	0.006
Ticlopidine	0.3584	1.431	0.917	2.232	0.1

Warfarin	0.1861	1.205	0.802	1.809	0.4
Dipyridamole	-0.0554	0.946	0.842	1.064	0.4
Nitrate	-0.0038	0.996	0.873	1.137	1.0
Statin	0.1767	1.193	1.12	1.272	<.0001
PPI	0.0966	1.101	0.905	1.34	0.3
NSAID	-0.2007	0.818	0.762	0.878	<.0001
Comorbidities					
Hypertension	0.2415	1.273	1.15	1.409	<.0001
Coronary artery disease	0.0595	1.061	0.996	1.131	0.07
Heart failure	0.0922	1.097	0.989	1.216	0.08
Peripheral vascular disease	-0.1435	0.866	0.768	0.977	0.02
Peptic ulcer disease	-0.0254	0.975	0.918	1.035	0.4
Liver disease	-0.0388	0.962	0.906	1.021	0.2
Chronic kidney disease	0.1233	1.131	1.04	1.23	0.004
Atrial fibrillation	0.1987	1.22	1	1.488	0.05
Dyslipidemia	-0.0311	0.969	0.915	1.027	0.3
Valvular heart disease	0.1532	1.166	1.045	1.299	0.006
Cancer	0.0337	1.034	0.935	1.144	0.5
Autoimmune disease	0.0631	1.065	0.925	1.226	0.4
Physical limitation	-0.0688	0.934	0.825	1.056	0.3

[a] Urbanization levels in Taiwan are divided into four strata according to the Taiwan National Health Research Institute publications. Level 1 designates the most urbanized areas, and level 4 designates the least urbanized areas.

[b] Charlson Comorbidity Index score is used to determine overall systemic health. With each increased level of CCI score, there are stepwise increases in the cumulative mortality.

[c] Adapted Diabetes Complications Severity Index is a 13-point scale from 7 complication categories: retinopathy, nephropathy, neuropathy, cerebrovascular, cardiovascular, peripheral vascular disease, and metabolic, ranging from each complication. Each complication produced a numeric score ranging from 0 to 2 (0 = no abnormality, 1 = some abnormality, 2 = severe abnormality)

Abbreviations: NT dollars, new Taiwan dollars; NSAID, Non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitors.